Author name: Leonardo Arias

With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter,” early stage biotechs are rewriting their financing strategies around nondilutive capital and targeted private wealth.

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

With CE mark approval, the pulsed field ablation procedure becomes available to treat patients in Europe with persistent atrial fibrillation.

Fresenius has issued a software release to address issues that could interrupt treatment with its Ivenix large volume pumps.

Evanko, currently the insurer’s COO, will assume the chief executive role after Cordani retires in July.

  En 2026, el panorama profesional ha alcanzado una paradoja de productividad. Los agentes de inteligencia artificial ahora pueden ejecutar estrategias de negocio de múltiples pasos en segundos, pero los riesgos legales y regulatorios asociados con estas acciones nunca han sido tan el …

Federal regulators are planning to suspend enrollment in Elevance’s MA plans by the end of March, in a rare and serious threat to the company’s finances.

A proposed rule would cull or revise dozens of health IT certification criteria, but providers say regulators should keep some of them to avoid shifting costs or compliance responsibilities back onto clinicians. 

This webinar explores how collaborative-initiated trials and Investigator-Initiated Trials (IITs) are complementing traditional drug development to accelerate innovation, advance precision medicine, and address clinically meaningful questions.

Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.